WHO Informal consultation for the guidelines on the nonclinical and clinical evaluation of monoclonal antibodies and related biological products intended for the prevention or treatment of human infectious diseases

An Informal Consultation on the draft WHO Guidelines on the nonclinical and clinical evaluation of monoclonal antibodies and related biological products intended  for the prevention or treatment of human infectious diseases was held at the Royal Society of Medicine, London, 28th-30th November 2022. Nineteen invited participants included members of the drafting group as well as representatives from academia, industry and regulatory authorities. In addition, six WHO staff participated either in person or virtually. The meeting was opened by Dr Richard Isbrucker (WHO, Norms & Standards for Biological Products (NSB) Team, Switzerland) who briefly outlined its objectives.